Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

Muhamed Baljevic, Jae H. Park, Eytan Stein, Dan Douer, Jessica K. Altman, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

Original languageEnglish (US)
Pages (from-to)1215-1233
Number of pages19
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 2011


  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Arsenic trioxide
  • Cure
  • Targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?'. Together they form a unique fingerprint.

Cite this